Inclusion Criteria:

- newly diagnosed GBM

- Diagnosis must be established by open biopsy or tumour resection

- Tumour must have a supratentorial component

- Over 18 years

- pre-treatment evaluations must be met

- study therapy to begin within 6 weeks of surgery

- KPS greater or equal to 70

- patients must sign informed consent

- If female, patients must not be pregnant or lactating

- Women of childbearing potential and male participants must practice adequate
contraception

Exclusion Criteria:

- prior invasive malignancy )except for non-melanomatous skin cancer) unless disease
free for greater than 3 years

- recurrent or multifocal malignant gliomas

- metastatic disease of leptomeningeal spread

- prior chemo or radiosensitizers for cancers of the head and neck region

- prior RT to head and neck region except for T1 glottic cancer, resulting in overlap
of radiation fields.

- Severe active co-morbidity define in protocol

- Pregnant of lactating women

- Women of childbearing potential or men who are sexually active who are not willing or
able to use medically acceptable forms of contraception; this exclusion is necessary
due to the treatment involved potentially being teratogenic.

- prior allergic reaction to temozolomide and/or dichloroacetate

- History of HIV/AIDS